SG acquires AstraZeneca's Evusheld

Evusheld is a long-acting antibody candidate for COVID-19 treatment.

The government of Singapore has signed a purchase agreement with AstraZeneca to deliver Evusheld, its long-acting antibody (LAAB) combination candidate, for the treatment of COVID-19.

The supply will arrive in Singapore by year-end.

"Evusheld provides healthcare professionals and patients in Singapore with a new option to fight the virus. Additionally, Evusheld will provide another prevention option for high-risk populations, alongside vaccines, including for people who are immunocompromised and unable to develop the needed degree of protective response following COVID-19 vaccination," AstraZeneca Singapore Country President Vinod Narayanan said.

A Phase III trial showed an 88% reduced risk of severe COVID-19 or death when patients with mild-to-moderate COVID-19 were treated within three days of symptom onset. AstraZeneca has this week received Emergency Use Authorization for Evusheld from the US Food and Drug Administration for the prevention of COVID-19 and has filed for regulatory approvals in other countries.